{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:10:35Z","timestamp":1793326235546,"version":"4.5.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001275","name":"The Oak Foundation USA","doi-asserted-by":"publisher","award":["OCAY-24-074-OFIL"],"award-info":[{"award-number":["OCAY-24-074-OFIL"]}],"id":[{"id":"10.13039\/100001275","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ard.2026.05.013","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T11:21:37Z","timestamp":1780658497000},"page":"1530-1542","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Composite outcome measures that successfully differentiate active treatments from placebo in psoriatic arthritis trials: a GRAPPA-OMERACT systematic review and network meta-analysis"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-8402-3917","authenticated-orcid":false,"given":"Tommy K","family":"Annfeldt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina N","family":"H\u00e4ndel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Haugegaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius","family":"Henriksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura C","family":"Coates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Ogdie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Tillett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niti","family":"Goel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dafna D","family":"Gladman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana-Maria","family":"Orbai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten","family":"de Wit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vibeke","family":"Strand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J","family":"Mease","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"FitzGerald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip S","family":"Helliwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Tugwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Ying","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ard.2026.05.013_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2021.101694","article-title":"Pathogenesis of psoriatic arthritis","volume":"35","author":"Stober","year":"2021","journal-title":"Best Pract Res Clin Rheumatol."},{"key":"10.1016\/j.ard.2026.05.013_bib0002","unstructured":"Freemantle N, Calvert M, Wood J, Eastaugh J, Griffin C. Composite outcomes in randomized trials greater precision but with greater uncertainty? [Internet]. Report. Available from: https:\/\/jamanetwork.com\/"},{"issue":"6","key":"10.1016\/j.ard.2026.05.013_bib0003","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/j.semarthrit.2021.11.001","article-title":"Composite outcomes at OMERACT: multi-outcome domains and composite outcome domains","volume":"51","author":"Wells","year":"2021","journal-title":"Semin Arthritis Rheum."},{"key":"10.1016\/j.ard.2026.05.013_bib0004","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3899\/jrheum.2023-0530","article-title":"Initiating evaluation of composite outcome measures for psoriatic arthritis: 2022 updates from the GRAPPA-OMERACT Working Group","volume":"50","author":"Leung","year":"2023","journal-title":"J Rheumatol."},{"issue":"4","key":"10.1016\/j.ard.2026.05.013_bib0005","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1136\/annrheumdis-2016-210242","article-title":"International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials","volume":"76","author":"Orbai","year":"2017","journal-title":"Ann Rheum Dis."},{"issue":"1","key":"10.1016\/j.ard.2026.05.013_bib0006","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/ard.2008.102053","article-title":"Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment","volume":"69","author":"Coates","year":"2010","journal-title":"Ann Rheum Dis."},{"issue":"8","key":"10.1016\/j.ard.2026.05.013_bib0007","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1136\/ard.2009.122259","article-title":"Application of the DAREA\/DAPSA score for assessment of disease activity in psoriatic arthritis","volume":"69","author":"Schoels","year":"2010","journal-title":"Ann Rheum Dis."},{"issue":"2","key":"10.1016\/j.ard.2026.05.013_bib0008","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/art.22552","article-title":"A proposed revision to the ACR20: the hybrid measure of American College of Rheumatology response","volume":"57","author":"Felson","year":"2007","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"6","key":"10.1016\/j.ard.2026.05.013_bib0009","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1136\/annrheumdis-2012-201341","article-title":"The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project)","volume":"72","author":"Helliwell","year":"2013","journal-title":"Ann Rheum Dis."},{"issue":"2","key":"10.1016\/j.ard.2026.05.013_bib0010","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1136\/ard.2010.129379","article-title":"Development of a preliminary composite disease activity index in psoriatic arthritis","volume":"70","author":"Mumtaz","year":"2011","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.ard.2026.05.013_bib0011","first-page":"39","article-title":"Composite measures for clinical trials in psoriatic arthritis: testing pain and fatigue modifications in a UK multicenter study","volume":"97","author":"Tillett","year":"2021","journal-title":"J Rheumatol Suppl."},{"key":"10.1016\/j.ard.2026.05.013_bib0012","first-page":"45","article-title":"Composite measures for routine clinical practice in psoriatic arthritis: testing of shortened versions in a UK multicenter study","volume":"97","author":"Tillett","year":"2021","journal-title":"J Rheumatol Suppl."},{"key":"10.1016\/j.ard.2026.05.013_bib0013","unstructured":"CHMP. Committee for Medicinal Products for human use (CHMP) guideline on clinical investigation of medicinal products for the treatment of psoriatic arthritis draft agreed by the efficacy working party adoption by CHMP for release for consultation end of CONSU\u2026 [Internet]. 2004 [cited 2026 Mar 29]. Available from: http:\/\/www.emea.europa.eu."},{"key":"10.1016\/j.ard.2026.05.013_bib0014","unstructured":"Beaton D, Maxwell L, Grosskleg S, Shea B, Tugwell P, editors. The OMERACT handbook for establishing and implementing core outcomes in clinical trials across the spectrum of rheumatologic conditions [Internet]. 2.1. OMERACT; 2021 [cited 2026 Jan 21]. Available from: https:\/\/omeract.org\/wp-content\/uploads\/2025\/11\/Handbook-June-2021-1.pdf"},{"issue":"11","key":"10.1016\/j.ard.2026.05.013_bib0015","doi-asserted-by":"crossref","DOI":"10.1136\/ard-2024-225566","article-title":"EULAR recommendations for the involvement of patient research partners in rheumatology research: 2023 update","volume":"83","author":"de Wit","year":"2024","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.ard.2026.05.013_bib0016","doi-asserted-by":"crossref","first-page":"n160","DOI":"10.1136\/bmj.n160","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ."},{"issue":"1","key":"10.1016\/j.ard.2026.05.013_bib0017","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/art.40726","article-title":"Special article: 2018 American College of Rheumatology\/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis","volume":"71","author":"Singh","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.ard.2026.05.013_bib0018","doi-asserted-by":"crossref","unstructured":"Gossec L, Baraliakos X, Kerschbaumer A. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Helena Marzo-Ortega. 2020;79:32. doi:10.1136\/annrheumdis-2020-217159","DOI":"10.1136\/annrheumdis-2020-217163"},{"issue":"8","key":"10.1016\/j.ard.2026.05.013_bib0019","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nat Rev Rheumatol."},{"key":"10.1016\/j.ard.2026.05.013_bib0020","unstructured":"Covidence systematic review software [Internet] Melbourne, Australia: Veritas Health Innovation; 2024 [cited 2024 Sep 16] Available from www.covidence.org."},{"key":"10.1016\/j.ard.2026.05.013_bib0021","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ."},{"issue":"2","key":"10.1016\/j.ard.2026.05.013_bib0022","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1136\/ard.2007.069690","article-title":"Responsiveness of patient reported outcomes including fatigue, sleep quality, activity limitation, and quality of life following treatment with abatacept for rheumatoid arthritis","volume":"67","author":"Wells","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.ard.2026.05.013_bib0023","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jclinepi.2012.01.012","article-title":"GRADE guidelines: 12. Preparing summary of findings tables - binary outcomes","volume":"66","author":"Guyatt","year":"2013","journal-title":"J Clin Epidemiol."},{"issue":"2","key":"10.1016\/j.ard.2026.05.013_bib0024","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jclinepi.2012.08.001","article-title":"GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles - continuous outcomes","volume":"66","author":"Guyatt","year":"2013","journal-title":"J Clin Epidemiol."},{"issue":"22","key":"10.1016\/j.ard.2026.05.013_bib0025","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1002\/1097-0258(20001130)19:22<3127::AID-SIM784>3.0.CO;2-M","article-title":"A simple method for converting an odds ratio to effect size for use in meta-analysis","volume":"19","author":"Chinn","year":"2000","journal-title":"Stat Med."},{"issue":"20","key":"10.1016\/j.ard.2026.05.013_bib0026","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1002\/sim.5356","article-title":"A multivariate meta-analysis approach for reducing the impact of outcome reporting bias in systematic reviews","volume":"31","author":"Kirkham","year":"2012","journal-title":"Stat Med."},{"key":"10.1016\/j.ard.2026.05.013_bib0027","series-title":"RStudio: Integrated Development Environment for R, version 2023.06.0","year":"2023"},{"issue":"1","key":"10.1016\/j.ard.2026.05.013_bib0028","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/annrheumdis-2013-203696","article-title":"Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)","volume":"73","author":"Mease","year":"2014","journal-title":"Ann Rheum Dis."},{"issue":"9","key":"10.1016\/j.ard.2026.05.013_bib0029","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1136\/annrheumdis-2016-210724","article-title":"Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis","volume":"76","author":"Mease","year":"2017","journal-title":"Ann Rheum Dis."},{"issue":"5","key":"10.1016\/j.ard.2026.05.013_bib0030","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1136\/annrheumdis-2018-214746","article-title":"Achieving remission in psoriatic arthritis by early initiation of TNF inhibition: a double-blind, randomised, placebo-controlled trial of golimumab plus methotrexate versus placebo plus methotrexate","volume":"78","author":"van MLJ","year":"2019","journal-title":"Ann Rheum Dis."},{"issue":"16","key":"10.1016\/j.ard.2026.05.013_bib0031","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","article-title":"Tofacitinib or adalimumab versus placebo for psoriatic arthritis","volume":"377","author":"Mease","year":"2017","journal-title":"N Engl J Med."},{"issue":"16","key":"10.1016\/j.ard.2026.05.013_bib0032","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","article-title":"Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors","volume":"377","author":"Gladman","year":"2017","journal-title":"N Engl J Med."},{"issue":"4","key":"10.1016\/j.ard.2026.05.013_bib0033","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1136\/annrheumdis-2019-216500","article-title":"GO-DACT: a phase 3b randomised, double-blind, placebo-controlled trial of GOlimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis","volume":"79","author":"Vieira-Sousa","year":"2020","journal-title":"Ann Rheum Dis."},{"issue":"11","key":"10.1016\/j.ard.2026.05.013_bib0034","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1002\/art.40226","article-title":"Safety and efficacy of intravenous golimumab in patients with active psoriatic arthritis: results through week twenty-four of the GO-VIBRANT Study","volume":"69","author":"Kavanaugh","year":"2017","journal-title":"Arthritis Rheumatol."},{"issue":"3","key":"10.1016\/j.ard.2026.05.013_bib0035","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s40744-019-0163-5","article-title":"Efficacy and safety of subcutaneous secukinumab 150 mg with or without loading regimen in psoriatic arthritis: results from the FUTURE 4 Study","volume":"6","author":"Kivitz","year":"2019","journal-title":"Rheumatol Ther."},{"issue":"10136","key":"10.1016\/j.ard.2026.05.013_bib0036","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/S0140-6736(18)30952-8","article-title":"Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study","volume":"391","author":"Deodhar","year":"2018","journal-title":"Lancet."},{"issue":"11","key":"10.1016\/j.ard.2026.05.013_bib0037","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1002\/acr.24046","article-title":"Composite measures of disease activity in psoriatic arthritis: comparative instrument performance based on the efficacy of guselkumab in an interventional phase II trial","volume":"72","author":"Helliwell","year":"2020","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"10086","key":"10.1016\/j.ard.2026.05.013_bib0038","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/S0140-6736(17)31429-0","article-title":"Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial","volume":"389","author":"Nash","year":"2017","journal-title":"Lancet."},{"issue":"7","key":"10.1016\/j.ard.2026.05.013_bib0039","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1002\/art.40851","article-title":"Etanercept and methotrexate as monotherapy or in combination for psoriatic arthritis: primary results from a randomized, controlled phase III trial","volume":"71","author":"Mease","year":"2019","journal-title":"Arthritis Rheumatol."},{"issue":"6","key":"10.1016\/j.ard.2026.05.013_bib0040","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1136\/annrheumdis-2017-212687","article-title":"Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study","volume":"77","author":"Mease","year":"2018","journal-title":"Ann Rheum Dis."},{"issue":"8","key":"10.1016\/j.ard.2026.05.013_bib0041","doi-asserted-by":"crossref","first-page":"894","DOI":"10.3899\/jrheum.210912","article-title":"Secukinumab in United States Biologic-Na\u00efve patients with psoriatic arthritis: results from the randomized, placebo-controlled CHOICE study","volume":"49","author":"Nguyen","year":"2022","journal-title":"J Rheumatol."},{"issue":"10222","key":"10.1016\/j.ard.2026.05.013_bib0042","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0140-6736(19)33161-7","article-title":"Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial","volume":"395","author":"Ritchlin","year":"2020","journal-title":"Lancet."},{"issue":"3","key":"10.1016\/j.ard.2026.05.013_bib0043","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1136\/annrheumdis-2020-218870","article-title":"Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2","volume":"80","author":"Mease","year":"2021","journal-title":"Ann Rheum Dis."},{"issue":"13","key":"10.1016\/j.ard.2026.05.013_bib0044","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa2022516","article-title":"Trial of upadacitinib and adalimumab for psoriatic arthritis","volume":"384","author":"McInnes","year":"2021","journal-title":"N Engl J Med."},{"issue":"10230","key":"10.1016\/j.ard.2026.05.013_bib0045","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","article-title":"Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Mease","year":"2020","journal-title":"Lancet."},{"issue":"10230","key":"10.1016\/j.ard.2026.05.013_bib0046","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","article-title":"Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF\u03b1 inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet."},{"key":"10.1016\/j.ard.2026.05.013_bib0047","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/rmdopen-2022-002559","article-title":"Efficacy and safety of tofacitinib in Chinese patients with active psoriatic arthritis: a phase 3, randomised, double-blind, placebo-controlled study","volume":"9","author":"Leng","year":"2023","journal-title":"RMD Open."},{"issue":"3","key":"10.1016\/j.ard.2026.05.013_bib0048","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/annrheumdis-2021-221048","article-title":"Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial","volume":"81","author":"\u00d6st\u00f6r","year":"2022","journal-title":"Ann Rheum Dis."},{"issue":"2","key":"10.1016\/j.ard.2026.05.013_bib0049","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1136\/annrheumdis-2021-221019","article-title":"Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial","volume":"81","author":"Kristensen","year":"2022","journal-title":"Ann Rheum Dis."},{"issue":"3","key":"10.1016\/j.ard.2026.05.013_bib0050","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1136\/annrheumdis-2021-220991","article-title":"Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS)","volume":"81","author":"Coates","year":"2022","journal-title":"Ann Rheum Dis."},{"issue":"10370","key":"10.1016\/j.ard.2026.05.013_bib0051","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0140-6736(22)02302-9","article-title":"Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)","volume":"401","author":"McInnes","year":"2023","journal-title":"Lancet."},{"issue":"10370","key":"10.1016\/j.ard.2026.05.013_bib0052","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0140-6736(22)02303-0","article-title":"Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-\u03b1 inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)","volume":"401","author":"Merola","year":"2023","journal-title":"Lancet."},{"issue":"6","key":"10.1016\/j.ard.2026.05.013_bib0053","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.semarthrit.2021.08.011","article-title":"The evolution of instrument selection for inclusion in core outcome sets at OMERACT: Filter 2.2","volume":"51","author":"Maxwell","year":"2021","journal-title":"Semin Arthritis Rheum."},{"key":"10.1016\/j.ard.2026.05.013_bib0054","doi-asserted-by":"crossref","DOI":"10.3899\/jrheum.2025-0268.C1","article-title":"Composite outcome measures for psoriatic arthritis: project updates 2024","author":"Ribeiro","year":"2025","journal-title":"J Rheumatol."},{"key":"10.1016\/j.ard.2026.05.013_bib0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2025.152907","article-title":"Determining the best discriminatory physical functioning outcome measurement instrument for psoriatic arthritis trials: a meta-epidemiological study","volume":"77","author":"Leung","year":"2026","journal-title":"Semin Arthritis Rheum."},{"key":"10.1016\/j.ard.2026.05.013_bib0056","unstructured":"Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions | Cochrane Training [Internet]. 5.1.0 (March 2011). Higgins JP, Green S, editors. [cited 2024 Apr 24]. Available from: https:\/\/training.cochrane.org\/handbook\/current"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496726002918?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496726002918?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T22:04:09Z","timestamp":1786485849000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496726002918"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":56,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0003496726002918"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2026.05.013","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Composite outcome measures that successfully differentiate active treatments from placebo in psoriatic arthritis trials: a GRAPPA-OMERACT systematic review and network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2026.05.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}